Respiratory Medicine

University of Tampere, Finland

Email: hannu.kankaanranta@epshp.fi

Qualifications

2011 Associate Professor (Docent) of Respiratory Medicine and Allergology, University of Tampere, Finland

2010 Professional Development (PD) Programme in Social and Health Management, University of Tampere, Finland

Publications (selected)

1. R. Korhonen, T. Hömmö, T. Keränen, M. Laavola, M. Hämäläinen, K. Vuolteenaho, L. Lehtimäki, H. Kankaanranta, E. Moilanen.Attenuation of TNF production and experimentally-induced inflammation by phosphodiesterase 4 inhibitor rolipram is mediated by mitogen-activated protein kinase phosphatase-1. Br J Pharmacol, in press, 2013. IF 4.409
2. P. Ilmarinen-Salo, E. Moilanen, V.L. Kinnula, H. Kankaanranta.Nitric oxide-induced eosinophil apoptosis is dependent on mitochondrial permeability transition (MPT), JNK and oxidative stress: apoptosis is preceded but not mediated by early mPT-dependent JNK activation. Respir Res 13: 73, 2012. IF 3.360
3. R.A. Brown, E. Leung, H. Kankaanranta, E. Moilanen, C.P. Page.Effects of heparin and related drugs on neutrophil function. Pulm Pharm Ther 25: 185-92, 2012. IF 2.800
4. M. Janka-Junttila, E. Moilanen, I.M. Adcock, H. Kankaanranta.Dexamethasone and RU24858 induce survival and Growth Factor receptor bound protein 2, leukotriene B4 receptor 1 and Annexin-1 expression in primary human neutrophils. J Cell Death 5: 21-29, 2012.
5. H. Kankaanranta, J. Parkkonen, P. Ilmarinen-Salo, M.A. Giembycz, E. Moilanen.Salbutamol delays human eosinophil apoptosis via a cAMP-dependent mechanism. Pulm Pharm Ther 24: 394-400, 2011. IF 2.800
6. S. Leivo-Korpela, L. Lehtimäki, K. Vuolteenaho, R. Nieminen, H. Kankaanranta, S. Saarelainen, E. Moilanen.Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma. J Inflamm (Lond) 8: 12, 2011. IF 2.263
7. P. Ilmarinen-Salo, E. Moilanen, H. Kankaanranta. Nitric oxide induces apoptosis in GM-CSF-treated eosinophils via caspase 6-dependent lamin and DNA fragmentation. Pulm Pharm Ther 23: 365-371, 2010.IF 2.800
8. L. Lehtimäki, P. Oksa, R. Järvenpää, T. Vierikko, R. Nieminen, H. Kankaanranta, J. Uitti, E. Moilanen. Pulmonary inflammation in asbestos-exposed subjects with borderline parenchymal changes on HRCT. Respir Med 104: 1042-1049, 2010.IF 2.475
9. H. Kankaanranta, M. Janka-Junttila, P. Ilmarinen-Salo, K. Ito, U. Jalonen, M. Ito, I.M. Adcock, E. Moilanen, X. Zhang. Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils. J Inflammation (Lond) 7: 9, 2010. IF 2.263
10. L. Lehtimäki, H. Kankaanranta, S. Saarelainen, I. Annila, T. Aine, R. Nieminen, E. Moilanen. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur Respir J 35: 72-78, 2010. IF 5.895
11. M. Crohns, K. Liippo, M. Erhola,H. Kankaanranta, E. Moilanen, H. Alho, P. Kellokumpu-Lehtinen. Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer. Clin Biochem 42: 1236-1245, 2009. IF 2.076
12. M. Crohns, S. Saarelainen, H. Kankaanranta, E. Moilanen, H. Alho, P. Kellokumpu-Lehtinen. Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy. Free Radical Res 43: 646-657, 2009. IF 2.878
13. M. Kerola, K. Vuolteenaho, O. Kosonen, H. Kankaanranta, S. Sarna, E. Moilanen.Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. Basic Clin Pharmacol 104: 17-21, 2009. IF 2.179
14. P. Ilmarinen, H. Hasala, O. Sareila, E. Moilanen, H. Kankaanranta. Bacterial DNA delays human eosinophil apoptosis. Pulm Pharm Ther 22: 167-176, 2009. IF 2.800
15. K. Tamminen, J. Laine, E. Soini, J. Martikainen, H. Kankaanranta. Cost-effectiveness of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments in Finland. Curr Med Res Opin 24: 3453-3461, 2008. IF 2.380
16. O. Sareila, R. Korhonen, H. Auvinen, M. Hämäläinen, H. Kankaanranta, E. Nissinen, E. Moilanen. The effects of levo- and dextrosimendan on NF-KB medicated transcription, iNOS expression and NO production in response to inflammatory stimuli. Br J Pharmacol 155: 884-895, 2008. IF 4.409
17. A. Sepponen, L. Lehtimäki, H. Huhtala, M. Kaila, H. Kankaanranta, E. Moilanen. Alveolar and bronchial nitric oxide output in healthy children. Pediatric Pulmonol 43: 1242-1248, 2008. IF 2.533
18. T. Leppänen, U. Jalonen, H. Kankaanranta, R. Tuominen, E. Moilanen.Inhibition of protein kinase C II downregulates tristetraprolin expression in activated macrophages. Inflamm Res 57:230-240, 2008. IF 2.109
19. R. Nieminen, K. Vuolteenaho, A. Riutta, H. Kankaanranta, P.M. van der Kraan, T. Moilanen, E. Moilanen.Aurothiomalate inhibits COX-2 expression in chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability. Eur J Pharmacol 587: 309-316, 2008. IF 2.516
20. T. Mäkinen, L. Lehtimäki, H. Kinnunen, R. Nieminen, H. Kankaanranta, E. Moilanen.Bronchial diffucing capacity of NO is increased in patients with allergic rhinitis. Int Arch Allergy Immunol 148: 154-160, 2009. IF 2.403
21. H. Perttunen, E. Moilanen, X. Zhang, P.J. Barnes, H. Kankaanranta. 2-agonists potentiate corticosteroid-induced neutrophil survival. COPD 5: 163-169, 2008. IF 1.794
22. O. Sareila, M. Hämäläinen, E. Nissinen, H. Kankaanranta, E. Moilanen.Orazipone decreases inducible nitric oxide synthase expression and nitric oxide production in activated macrophages and epithelial cells. J Pharm Exp Ther 324: 858-866, 2008. IF 3.828
23. J. Parkkonen, H. Hasala, E. Moilanen, M.A. Giembycz, H. Kankaanranta. PDE4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol. Pulm Pharm Ther 21:499-506, 2008. IF 2.800